Navigation Links
Allegheny Health Network Allergist Opposes OTC Sales of Corticosteroids in FDA Testimony, Citing Safety Concerns
Date:7/31/2013

Silver Spring, Md. (PRWEB) July 31, 2013

David P. Skoner, MD, Director of the Division of Allergy, Asthma and Immunology, Department of Medicine at Allegheny General Hospital (AGH), will testify today before the U.S. Food and Drug Administration in opposition to making triamcinolone acetonide nasal spray available over the counter. Currently, triamcinolone acetonide nasal spray is available only by prescription.

Dr. Skoner was chosen to represent the positions of both the American Academy of Allergy, Asthma and Immunology (AAAAI) and the American College of Allergy, Asthma and Immunology (ACAAI) in recommending against over-the-counter sales of triamcinolone acetonide nasal spray (brand names include Nasacort) due to safety concerns.

Corticosteroids hold the potential for causing adverse effects on a patient’s eyes, bones, hypothalamic-pituitary-adrenal glands, and to stunt a child’s growth, Dr. Skoner said. The effects can be insidious and not noticed for several years. In addition, Dr. Skoner said, patients could have access to corticosteroids in other forms, raising the potential for adverse effects. The effect of combining inhaled nasal corticosteroids with other inhaled steroids has not been studied.

Drug manufacturer Sanofi-Aventis US has asked the FDA for permission to sell triamcinolone acetonide nasal spray over the counter. It is used to relieve the symptoms of hay fever or other upper respiratory allergies, including nasal congestion, runny nose, sneezing and itching.

The most recent research shows that intranasal corticosteroids can stunt a child’s growth, but the long-term effects, including the child’s final adult height, are unknown, Dr. Skoner said.

The AAAAI and ACAAI recommend using triamcinolone acetonide only under the supervision of an appropriately trained medical provider, Dr. Skoner said. He reviewed the case of a 6-year-old girl who used both inhaled and inhaled-nasal corticosteroids to treat cough and allergies to tree and grass pollen, mold and dust mites. Over a period of time, the treatment suppressed her adrenal function and she nearly died of an infection and hypotension.

“Photos of this child tell an unbelievable story, showing steadily progressive changes in physical appearance as a result of hypercorticism,” Dr. Skoner said. Direct quotes from her mother were: “Truly unbelievable if this drug makes it over the counter!” and “My child will need to be on growth hormone shots every day until she goes through puberty, as a result of her growth suppression that never corrected itself.”

“The decision to switch inhaled nasal corticosteroids to over-the-counter status will undoubtedly cause growth and adrenal suppression in a large number of children,” Dr. Skoner said. “The correct monitoring of these drugs’ systemic effects, and needed adjustment of dosing, can only be done in a health care setting.”

Read the full story at http://www.prweb.com/releases/2013/7/prweb10984638.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Study by Allegheny General Hospital Physicians Shows Oral Immunotherapy is a Safe, Effective Alternative to Allergy Shots for Ragweed Sufferers
2. West Penn Allegheny Health System is First in Pennsylvania to Perform Groundbreaking Minimally-Invasive Procedure for Swallowing Disorder
3. West Penn Allegheny Health System Physicians Pinpoint Gastroesophageal Reflux Disease (GERD) as a Factor That May Cause Chronic Cough
4. You Survived Cancer: Now Pay Attention to Your Overall Health
5. NIH awards $20 million over 5 years to train next generation of global health researchers
6. Weill Cornell Medical College establishes Center for Healthcare Informatics and Policy
7. Esophageal Cancer Surgery Can Leave Lingering Health Problems, Study Says
8. Climate Change Could Be Tough on Seniors Health: Study
9. Supporting LGB children may influence their long-term health, BU study finds
10. U.S. Spends Too Little on Public Health Initiatives: Report
11. Optimal care of bariatric surgery patients vital for long-term health and well-being
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... ... February 09, 2016 , ... Ross A. Clevens, MD, ... to welcome a new addition to their growing practice. Beginning this month, Teresa ... nurse practitioner performing cosmetic procedures including injectables, fillers and laser treatments. ...
(Date:2/9/2016)... ... February 09, 2016 , ... Steven Douglas Associates is a ... Florida Event, an upscale fundraiser held in South Florida. The Inaugural What’s Your Taste ... This year the event will be held in a new, more causal format at ...
(Date:2/9/2016)... ... February 09, 2016 , ... ... production of its newest mobility device, the StandUp Walker. Made entirely in the ... in the last 50 years. , StandUp Walker’s novel patent-pending design offers 2-in-1 ...
(Date:2/9/2016)... Springs, FL (PRWEB) , ... February 09, 2016 ... ... leading innovative specialty pharmacies, announces today the continuation of the ‘Pay It Forward’ ... for each prescription referral received at our specialty pharmacy. , “Since our ...
(Date:2/9/2016)... ... February 09, 2016 , ... The Bon-Ton Stores, Inc. (NASDAQ: ... stores, announced it has raised $176,000 to benefit the Breast Cancer Research Foundation, ... at the University of Iowa, The Lynn Sage Cancer Research Foundation, and Masonic ...
Breaking Medicine News(10 mins):
(Date:2/10/2016)... , Feb. 9, 2016 On ... Administration (FDA) met with its Arthritis Advisory ... biosimilar of Johnson & Johnson,s Remicade and ... approved in the U.S. The Biologics Prescribers ... groups - Alliance for Patient Access, American ...
(Date:2/9/2016)... Calif. , Feb. 9, 2016 /PRNewswire/ - Nevro ... company that is providing innovative evidence-based solutions for the ... release financial results for the fourth quarter and full ... 29, 2016. Company management will host a conference call ... Time) on Monday, February 29, 2016. www.nevro.com ...
(Date:2/9/2016)... 9, 2016  Sangamo BioSciences, Inc. (NASDAQ: ... today reported its fourth quarter and full year ... vivo therapeutic genome editing," said Edward Lanphier, ... finger nuclease (ZFN) technology leads the therapeutic genome ... competencies necessary to move our ground-breaking genome editing ...
Breaking Medicine Technology: